GALT — Galectin Therapeutics Share News
0.000.00%
Last trade - 00:00- $340.87m
- $465.30m
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study
Brief: Galectin Therapeutics Announces Publication Of Navigate Phase 2B Trial Results For Belapectin In The Journal Of Hepatology
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs
Brief: Galectin Therapeutics Enters Line Of Credit Agreement
Brief: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response
Galectin Therapeutics Q3 loss narrows
Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Natgas companies, Eli Lilly, Kraft Heinz
U.S. STOCKS ON THE MOVE-Red Cat, Nvidia Corp, Redwire
H.C. Wainwright starts coverage of Galectin Therapeutics with 'buy'
Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Galectin Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Galectin Therapeutics Inc - Reports Significant Reduction In New Varices With Belapectin